The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Dara plus dex in R/R myeloma patients with renal impairment
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the results of the Phase II DARE study (NCT03450057), investigating the combination of daratumumab (dara) and dexamethasone (dex) in patients with relapsed/refractory (R/R) multiple myeloma with renal impairment. The study found that dara+dex achieved rapid hematologic responses in patients with R/R myeloma and severe renal impairments, with many patients also experiencing a major renal response. This line of treatment also resulted in impressive progression-free survival rates. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
